PLC Plc Systems,

Company Reports Fourth Quarter and 2006 Results; Provides Update on RenalGuard(TM) Product Initiative FRANKLIN, Mass., March 21 /PRNewswire-FirstCall/ -- PLC Systems Inc. (AMEX:PLC), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it has reached definitive agreement with Edwards Lifesciences LLC (NYSE:EW), which had been its exclusive sales and marketing partner for TMR products and services in the U.S., to assign this distribution agreement to Novadaq Corp., a wholly-owned U.S. subsidiary of Novadaq Technologies, Inc. (TSX: NDQ), a developer of medical imaging systems for the operating room. Following that assignment, PLC and Novadaq signed a new exclusive distribution agreement. "Today, we are taking a major step for our TMR business by naming a new partner in Novadaq," said Mark R. Tauscher, president and chief executive officer of PLC Systems. "We, and Novadaq, see strong synergistic opportunities for our TMR products used in real-time in conjunction with Novadaq's SPY(R) Intra-operative Imaging System, for which Novadaq recently built a direct US sales team that targets the same end user as we do, the cardiac surgeon. We appreciate the support of Edwards throughout the launch and building of our TMR business, but recognize that its focus has now moved in other directions, and we are pleased to find a new and able partner in Novadaq to make this a seamless transition for our growing customer base." For the exclusive United States distribution rights, Novadaq will pay Edwards cash consideration in the amount of $1 million at closing, an earn-out for the balance of 2007 which is estimated to be $3 million and a final payment of $3 million which is deferred under a one-year secured promissory note. Novadaq will also purchase Edwards' inventory and certain property used in its distribution of TMR at Edwards' net book value. Subsequently, PLC has reached a new distribution agreement with Novadaq enabling Novadaq to assume a similar role, effective immediately, as PLC's exclusive distributor for its TMR products in the U.S. Currently, Novadaq's U.S. sales force includes direct sales people and clinical educators, all focused on the cardiac surgery customer base, which parallels the customer contact for TMR, and Novadaq intends to expand this team by hiring Edwards' existing U.S. laser sales force. Mr. Tauscher added, "This has been a pivotal year for PLC, with the announcement in mid-September of our new product initiative, RenalGuard(TM), which we believe will enable us to achieve greater long-term growth than we would by focusing on TMR alone. The revenue stream from the TMR business enables us to drive forward on RenalGuard's clinical program. We remain very excited about the major market opportunity for RenalGuard in preventing Contrast-Induced Nephropathy (CIN), a serious side effect that can result in patient death and that affects at risk patients, who constitute a meaningful portion of the millions of people undergoing imaging procedures worldwide. We continue to work aggressively with institutions to secure approval of our protocol, and while we are encountering some institutional research approval delays, just last week, we announced that the first patients had been successfully treated at Cape Cod Hospital. We continue working toward securing CE Mark approval for RenalGuard therapy by the middle of 2007, followed by initial international distribution starting in the second half of 2007. We are currently targeting FDA approval and the launch of U.S. distribution by the middle of 2009. We continue to see a potential market opportunity for RenalGuard of some $500 million, and we are very excited about our plan to pursue this market aggressively." Fourth Quarter and Year Results The company also today reported financial results for the three and twelve months ended December 31, 2006. Fourth quarter 2006 total revenues were $1,747,000 compared with $1,811,000 in the fourth quarter of 2005. The net income for the fourth quarter of 2006 was $36,000, or $0.00 per diluted share, compared to a net loss of $397,000, or a loss of $.0.01 per diluted share, in the fourth quarter of 2005. Total revenues for 2006 were $7,146,000 compared to total revenues of $7,636,000 for 2005. Net income for 2006 was $1,319,000, or $0.04 per diluted share, compared to a net loss of $1,268,000, or a loss of $0.04 per diluted share, for 2005. 2006's net income reflects a gain of $1,432,000 in the first quarter of 2006 from the sale of the company's Optiwave disposable manufacturing rights to Edwards. During the fourth quarter of 2006, PLC shipped four new CO2 Heart Lasers (HL2) to U.S. hospitals through Edwards. PLC ended 2006 with 156 HL2 CO2 Heart Lasers located at heart centers throughout the U.S. Also during the fourth quarter of 2006, a total of 509 disposable kits were shipped worldwide by Edwards and PLC. Edwards delivered 466 of these kits to U.S. hospitals and PLC shipped 43 disposable kits to international customers. In comparison, a total of 555 disposable kits were delivered worldwide during the fourth quarter of 2005. Conference Call PLC Systems will be hosting a conference call today, March 21, at 4:00 p.m. Eastern Time to discuss these matters. The call may be joined by dialing (866) 202-0886, or internationally, (617) 213-8841, at least five minutes prior to the start of the call. The passcode is: 59124812. A live webcast of the call will be accessible at the investor relations section of the Company's website at http://www.plcmed.com/. An archived webcast of the conference call will be available beginning one hour after the completion of the call in the same location. A replay of the call can also be accessed telephonically by dialing 888-286-8010, or internationally 617-801-6888, using passcode 19634817, from 6 pm on March 21, 2007 through midnight March 28, 2007. About PLC Systems Inc. PLC Systems Inc. (AMEX:PLC) is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Mass., PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. CO2 TMR offers a treatment option for angina patients who suffer from severe coronary artery disease. The CO2 Heart Laser is the world's first TMR angina relief device approved by both the U.S. Food and Drug Administration and Japanese Ministry of Health, Labor and Welfare. In addition, the company recently initiated clinical studies for its RenalGuard(TM) Therapy and RenalGuard(TM) System. Renal Guard Therapy is a fully-automated, matched fluid replacement system intended for interventional cardiology and radiology patients undergoing diagnostic and therapeutic imaging procedures where contrast agents are administered. Additional company information can be found at http://www.plcmed.com/. This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including Novadaq may be unsuccessful in selling our products, the transition period following Novadaq's new role as our exclusive US distributor may adversely affect our revenues, we and Novadaq may be unable to convince health care professionals and third party payers of the medical and economic benefits of performing TMR, there can be no assurance that all payers will reimburse health care providers who perform TMR procedures or that reimbursement, if provided, will be adequate, we may not receive necessary regulatory approvals to market our RenalGuard product, the clinical trials for that product may not be successful, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in our Report on Form 10-K for the year ended December 31, 2005, and our other SEC reports. PLC Systems, PLC Medical Systems, PLC and CO2 Heart Laser and RenalGuard are trademarks of PLC Systems Inc. Edwards Lifesciences is a trademark of Edwards Lifesciences Corporation. Novadaq and SPY are trademarks of Novadaq Technologies, Inc. Contact: Mary T. Conway Conway Communications 617-244-9682 PLC SYSTEMS INC. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) Three Months Ended Year Ended December 31, December 31, 2006 2005 2006 2005 Revenues: Product sales -- Edwards $1,201 $1,278 $4,918 $5,476 Product sales -- other 199 159 744 621 Service fees -- Edwards 320 327 1,354 1,311 Service fees -- other 27 47 130 228 Total revenues 1,747 1,811 7,146 7,636 Cost of revenues: Product sales -- Edwards 472 485 1,644 2,064 Product sales -- other 72 48 387 252 Service fees -- Edwards 145 142 550 577 Service fees -- other 40 58 151 173 Total cost of revenues 729 733 2,732 3,066 Gross profit 1,018 1,078 4,414 4,570 Operating expenses: Selling, general and administrative 544 820 3,014 3,336 Research and development 539 720 1,924 2,750 Total operating expenses 1,083 1,540 4,938 6,086 Gain on the sale of manufacturing rights -- -- 1,432 -- Income (loss) from operations (65) (462) 908 (1,516) Other income, net 126 65 436 248 Income (loss) before income taxes 61 (397) 1,344 (1,268) Provision for income taxes 25 -- 25 -- Net income (loss) $36 $(397) $1,319 $(1,268) Basic and diluted income (loss) per share $0.00 $(0.01) $0.04 $(0.04) Average shares outstanding: Basic 30,268 30,079 30,170 30,074 Diluted 30,723 30,079 30,572 30,074 CONDENSED BALANCE SHEET December 31, December 31, 2006 2005 Cash and short-term investments $10,034 $9,460 Total current assets 12,802 12,008 Total assets 13,176 12,467 Total current liabilities 2,953 3,044 Shareholders' equity 7,129 5,543 DATASOURCE: PLC Systems CONTACT: Mary T. Conway of Conway Communications, +1-617-244-9682, Web site: http://www.plcmed.com/

Copyright